Edwards Lifesciences Co. (NYSE:EW) Stake Trimmed by Vinva Investment Management Ltd

Vinva Investment Management Ltd lessened its stake in shares of Edwards Lifesciences Co. (NYSE:EW) by 60.2% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 10,011 shares of the medical research company’s stock after selling 15,135 shares during the period. Vinva Investment Management Ltd’s holdings in Edwards Lifesciences were worth $667,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of EW. First Community Trust NA acquired a new stake in shares of Edwards Lifesciences in the second quarter worth $29,000. Webster Bank N. A. acquired a new position in Edwards Lifesciences during the second quarter valued at $39,000. Versant Capital Management Inc lifted its stake in Edwards Lifesciences by 206.3% in the 2nd quarter. Versant Capital Management Inc now owns 484 shares of the medical research company’s stock worth $45,000 after acquiring an additional 326 shares in the last quarter. Prospera Private Wealth LLC acquired a new stake in Edwards Lifesciences during the 3rd quarter worth about $32,000. Finally, Avior Wealth Management LLC grew its stake in Edwards Lifesciences by 138.7% during the 3rd quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company’s stock valued at $35,000 after acquiring an additional 308 shares in the last quarter. 79.46% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research firms recently commented on EW. Sanford C. Bernstein upgraded shares of Edwards Lifesciences from a “strong sell” rating to a “hold” rating in a report on Monday, October 28th. Citigroup cut their target price on shares of Edwards Lifesciences from $83.00 to $77.00 and set a “buy” rating for the company in a research report on Tuesday, October 1st. JPMorgan Chase & Co. boosted their price target on shares of Edwards Lifesciences from $72.00 to $78.00 and gave the company a “neutral” rating in a report on Friday, October 25th. Barclays cut their price objective on Edwards Lifesciences from $90.00 to $80.00 and set an “overweight” rating for the company in a report on Monday, September 9th. Finally, Jefferies Financial Group downgraded Edwards Lifesciences from a “buy” rating to a “hold” rating and lowered their target price for the company from $85.00 to $70.00 in a research note on Wednesday, September 18th. Seventeen equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the company. According to MarketBeat.com, the company has an average rating of “Hold” and an average target price of $76.85.

Insiders Place Their Bets

In other news, insider Larry L. Wood sold 25,000 shares of the business’s stock in a transaction that occurred on Tuesday, November 5th. The stock was sold at an average price of $65.91, for a total transaction of $1,647,750.00. Following the sale, the insider now directly owns 198,526 shares in the company, valued at approximately $13,084,848.66. The trade was a 11.18 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of the company’s stock in a transaction on Wednesday, September 11th. The shares were sold at an average price of $66.77, for a total value of $333,850.00. Following the completion of the transaction, the vice president now owns 46,936 shares of the company’s stock, valued at $3,133,916.72. The trade was a 9.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 40,000 shares of company stock worth $2,657,000 in the last ninety days. Insiders own 1.29% of the company’s stock.

Edwards Lifesciences Price Performance

NYSE EW opened at $71.35 on Friday. The stock has a market capitalization of $42.08 billion, a PE ratio of 10.30, a P/E/G ratio of 4.05 and a beta of 1.12. The stock has a 50-day simple moving average of $68.10 and a 200 day simple moving average of $75.15. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46. Edwards Lifesciences Co. has a twelve month low of $58.93 and a twelve month high of $96.12.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings data on Thursday, October 24th. The medical research company reported $0.67 earnings per share for the quarter, meeting the consensus estimate of $0.67. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. The company had revenue of $1.35 billion during the quarter, compared to analysts’ expectations of $1.57 billion. During the same period in the prior year, the business earned $0.59 earnings per share. Edwards Lifesciences’s revenue for the quarter was up 8.9% compared to the same quarter last year. Research analysts anticipate that Edwards Lifesciences Co. will post 2.57 EPS for the current year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.